GleamWall
中文EN

VKTX Viking Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1607678 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-164.2%
TTM EPS YoY-155.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-96.4%
ROA-73.1%
ROIC (approx.)-195.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets39.8%
Debt / equity0.00x
Current ratio7.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-19.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$344.95M$101.64M
SG&A expense$48.39M$49.28M
Operating income-$393.34M-$150.92M
Pretax income-$359.64M-$109.96M
Income tax$1,000$1,000
Net income-$359.64M-$109.96M
EPS (basic)-3.19-1.01
EPS (diluted)-3.19-1.01
Weighted avg. shares (diluted)112.67M109.04M
Balance sheet
Cash & equivalents$165.81M$26.68M
Short-term investments$539.93M$875.94M
Current assets$715.60M$907.22M
Total assets$715.73M$908.32M
Current liabilities$76.67M$27.41M
Total liabilities$76.67M$28.04M
Shareholders' equity$639.06M$880.28M
Shares outstanding114.79M111.57M
Cash flow statement
Operating cash flow-$278.69M-$87.79M
Investing cash flow$341.39M-$553.37M
Financing cash flow$76.44M$612.46M
Stock-based compensation$40.82M$29.71M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.